Literature DB >> 22783453

Surgical protocol in patients at risk for bisphosphonate osteonecrosis of the jaws: clinical use of serum telopetide CTX in preventive monitoring of surgical risk.

Fabrizio Carini1, Vito Saggese, Gianluca Porcaro, Lorena Barbano, Marco Baldoni.   

Abstract

AIM: This study investigates the association between cross linked C-terminal telopetide test (CTX) and individual surgical risk of osteonecrosis in patients taking oral bisphosphonates.
MATERIALS AND METHODS: 32 patients receiving bisphosphonate were treated surgically. Patients were divided into three groups according to type of drug administrated and were subjected to a treatment of oral surgery, such as simple tooth extractions and extraction of all residual teeth of the oral cavity, upon evaluation of CTX values and antibiotic prophylaxis.
RESULTS: Within the sample of 32 patients, 12 patients had been treated with bisphosphonates for several years and none developed osteonecrosis of the jaw upon surgery. As for CTX, patients treated with oral bisphosphonates showed a mean value of serum Ctelopetides of 0.2869 ng/ml. The mean value of CTX did not differ significantly between patients taking oral bisphosphonates and healthy patients not treated with bisphosphonates.
CONCLUSION: None of the patients subjected to preoperative antibiotic prophylaxis developed osteonecrosis of the jaw after surgery. The pharmacological and surgical protocol tested appeared valid in the prevention of osteonecrosis associated to bisphosphonates.

Entities:  

Keywords:  bisphosphonate; osteonecrosis of the jaw (ONJ); serum C-terminal C-telopeptide (CTX)

Year:  2012        PMID: 22783453      PMCID: PMC3392664     

Source DB:  PubMed          Journal:  Ann Stomatol (Roma)        ISSN: 1824-0852


  10 in total

1.  Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy.

Authors:  H N Rosen; A C Moses; J Garber; I D Iloputaife; D S Ross; S L Lee; S L Greenspan
Journal:  Calcif Tissue Int       Date:  2000-02       Impact factor: 4.333

2.  Clinical concerns of alendronate use.

Authors:  James L Rutkowski; David A Johnson; Douglas M Smith
Journal:  J Oral Maxillofac Surg       Date:  2007-02       Impact factor: 1.895

3.  Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer.

Authors:  Salvatore Ruggiero; Julie Gralow; Robert E Marx; Ana O Hoff; Mark M Schubert; Joseph M Huryn; Bela Toth; Kathryn Damato; Vicente Valero
Journal:  J Oncol Pract       Date:  2006-01       Impact factor: 3.840

4.  Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study.

Authors:  Paul D Miller; Michael R McClung; Liviu Macovei; Jacob A Stakkestad; Marjorie Luckey; Bernard Bonvoisin; Jean-Yves Reginster; Robert R Recker; Claire Hughes; E Michael Lewiecki; Dieter Felsenberg; Pierre D Delmas; David L Kendler; Michael A Bolognese; Nicole Mairon; Cyrus Cooper
Journal:  J Bone Miner Res       Date:  2005-03-14       Impact factor: 6.741

5.  Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.

Authors:  Robert E Marx; Yoh Sawatari; Michel Fortin; Vishtasb Broumand
Journal:  J Oral Maxillofac Surg       Date:  2005-11       Impact factor: 1.895

Review 6.  Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws.

Authors:  Sook-Bin Woo; John W Hellstein; John R Kalmar
Journal:  Ann Intern Med       Date:  2006-05-16       Impact factor: 25.391

7.  Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment.

Authors:  Robert E Marx; Joseph E Cillo; Juan J Ulloa
Journal:  J Oral Maxillofac Surg       Date:  2007-12       Impact factor: 1.895

8.  Reconstruction of defects caused by bisphosphonate-induced osteonecrosis of the jaws.

Authors:  Robert E Marx
Journal:  J Oral Maxillofac Surg       Date:  2009-05       Impact factor: 1.895

9.  Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases.

Authors:  Salvatore L Ruggiero; Bhoomi Mehrotra; Tracey J Rosenberg; Stephen L Engroff
Journal:  J Oral Maxillofac Surg       Date:  2004-05       Impact factor: 1.895

10.  Ten years' experience with alendronate for osteoporosis in postmenopausal women.

Authors:  Henry G Bone; David Hosking; Jean-Pierre Devogelaer; Joseph R Tucci; Ronald D Emkey; Richard P Tonino; Jose Adolfo Rodriguez-Portales; Robert W Downs; Jayanti Gupta; Arthur C Santora; Uri A Liberman
Journal:  N Engl J Med       Date:  2004-03-18       Impact factor: 91.245

  10 in total
  1 in total

Review 1.  Serum C-terminal cross-linking telopeptide level as a predictive biomarker of osteonecrosis after dentoalveolar surgery in patients receiving bisphosphonate therapy: Systematic review and meta-analysis.

Authors:  Mohamed E Awad; Christina Sun; Joshua Jernigan; Mohammed Elsalanty
Journal:  J Am Dent Assoc       Date:  2019-06-28       Impact factor: 3.634

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.